Literature DB >> 8147899

Interaction of ebselen with glutathione S-transferase and papain in vitro.

T Nikawa1, G Schuch, G Wagner, H Sies.   

Abstract

The interaction of ebselen(2-phenyl-1,2-benzisoselenazol-3(2H)-one) with rat liver cytosolic glutathione S-transferases (GSTs) and the plant cysteine protease, papain, was studied as cysteine residues are important for the activity of these enzymes. The capacity of GST 1-2 and 3-4 for ebselen binding is similar (1.5 mol ebselen/mol GST isozyme), while GST 2-2 and GST 7-7 bind 0.3 and more than 2.0 mol ebselen/mol GST isozyme, respectively. Ebselen does not bind to N-ethylmaleimide-treated GST, and its binding to GST is prevented by 5 mM thiols. Ebselen irreversibly inactivates the different GST isozymes with a second order rate constant ranging from 20 to 2250 M-1 sec-1 for the different subunits. GST inhibition by ebselen is partially restored by 5 mM thiols. Ebselen binds to untreated papain and to cysteine-treated papain at a ratio of about 0.1 and 0.75 mol ebselen/mol papain, respectively. Ebselen does not bind to N-ethylmaleimide-treated papain, and its binding to papain is interfered with by added thiols. Papain is inactivated by ebselen with a second order rate constant of 1800 M-1 sec-1 in the absence of thiols. However, in the presence of GSH, 2-mercaptoethanol or sodium borohydride, ebselen exerts an activating effect on papain. The binding of ebselen by a seleno-sulfide bond to cysteine residues of GSTs and papain leads to their inactivation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8147899     DOI: 10.1016/0006-2952(94)90411-1

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  10 in total

1.  High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.

Authors:  Matthew J Saunders; Steven W Graves; Larry A Sklar; Tudor I Oprea; Bruce S Edwards
Journal:  Assay Drug Dev Technol       Date:  2010-02       Impact factor: 1.738

2.  Reaction kinetics and targeting to cellular glutathione S-transferase of the glutathione peroxidase mimetic PhSeZnCl and its D,L-polylactide microparticle formulation.

Authors:  D Bartolini; M Piroddi; C Tidei; S Giovagnoli; D Pietrella; Y Manevich; K D Tew; D Giustarini; R Rossi; D M Townsend; C Santi; F Galli
Journal:  Free Radic Biol Med       Date:  2014-10-18       Impact factor: 7.376

3.  Identification of small molecules that inhibit the interaction of TEM8 with anthrax protective antigen using a FRET assay.

Authors:  Lorna M Cryan; Kaiane A Habeshian; Thomas P Caldwell; Meredith T Morris; P Christine Ackroyd; Kenneth A Christensen; Michael S Rogers
Journal:  J Biomol Screen       Date:  2013-03-11

4.  Screening for dimethylarginine dimethylaminohydrolase inhibitors reveals ebselen as a bioavailable inactivator.

Authors:  Thomas Linsky; Yun Wang; Walter Fast
Journal:  ACS Med Chem Lett       Date:  2011       Impact factor: 4.345

5.  Identification and characterization of novel classes of macrophage migration inhibitory factor (MIF) inhibitors with distinct mechanisms of action.

Authors:  Hajer Ouertatani-Sakouhi; Farah El-Turk; Bruno Fauvet; Min-Kyu Cho; Damla Pinar Karpinar; Didier Le Roy; Manfred Dewor; Thierry Roger; Jürgen Bernhagen; Thierry Calandra; Markus Zweckstetter; Hilal A Lashuel
Journal:  J Biol Chem       Date:  2010-06-01       Impact factor: 5.157

6.  A seleno-hormetine protects bone marrow hematopoietic cells against ionizing radiation-induced toxicities.

Authors:  Desirée Bartolini; Yanzhong Wang; Jie Zhang; Daniela Giustarini; Ranieri Rossi; Gavin Y Wang; Pierangelo Torquato; Danyelle M Townsend; Kenneth D Tew; Francesco Galli
Journal:  PLoS One       Date:  2019-04-29       Impact factor: 3.240

7.  Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors.

Authors:  Chunlong Ma; Yanmei Hu; Julia Alma Townsend; Panagiotis I Lagarias; Michael Thomas Marty; Antonios Kolocouris; Jun Wang
Journal:  ACS Pharmacol Transl Sci       Date:  2020-10-09

Review 8.  Modulation of Insulin Sensitivity by Insulin-Degrading Enzyme.

Authors:  Carlos M González-Casimiro; Beatriz Merino; Elena Casanueva-Álvarez; Tamara Postigo-Casado; Patricia Cámara-Torres; Cristina M Fernández-Díaz; Malcolm A Leissring; Irene Cózar-Castellano; Germán Perdomo
Journal:  Biomedicines       Date:  2021-01-17

9.  Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19.

Authors:  Hengrui Liu; Sho Iketani; Arie Zask; Nisha Khanizeman; Eva Bednarova; Farhad Forouhar; Brandon Fowler; Seo Jung Hong; Hiroshi Mohri; Manoj S Nair; Yaoxing Huang; Nicholas E S Tay; Sumin Lee; Charles Karan; Samuel J Resnick; Colette Quinn; Wenjing Li; Henry Shion; Xin Xia; Jacob D Daniels; Michelle Bartolo-Cruz; Marcelo Farina; Presha Rajbhandari; Christopher Jurtschenko; Matthew A Lauber; Thomas McDonald; Michael E Stokes; Brett L Hurst; Tomislav Rovis; Alejandro Chavez; David D Ho; Brent R Stockwell
Journal:  Nat Commun       Date:  2022-04-07       Impact factor: 17.694

10.  In Vitro Efficacy of Ebselen and BAY 11-7082 Against Naegleria fowleri.

Authors:  Anjan Debnath; Andrew T Nelson; Angélica Silva-Olivares; Mineko Shibayama; Dionicio Siegel; James H McKerrow
Journal:  Front Microbiol       Date:  2018-03-06       Impact factor: 5.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.